New Developments from the REZOLVE-AD Study
SAN FRANCISCO — Nektar Therapeutics (NASDAQ: NKTR) has recently announced that compelling data from the ongoing REZOLVE-AD Phase 2b study featuring rezpegaldesleukin, an innovative IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, will be showcased in a late-breaking oral abstract presentation at the forthcoming annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI).
Presentation Details
The ACAAI 2025 Annual Scientific Meeting will take place in Orlando, USA. The presentation is scheduled for Saturday, November 8, 2025, at 5:33 PM ET. Dr. Jonathan Corren will present the findings during a session emphasizing distinguished industry and late-breaking oral abstracts.
What Will Be Presented?
- Abstract ID: 7005
- Oral Topic: "Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial"
- Location: Room W231
Following the presentation, viewers will be able to access the results on Nektar's official website under the Scientific Publications section.
Insights into the REZOLVE-AD Phase 2b Study
The REZOLVE-AD study is a global clinical trial that aims to understand the effectiveness of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The study currently has enrolled 393 patients who had not previously received treatment with biologics or JAK inhibitors, making it a significant investigation in the field.
During the initial 16-week induction treatment period, participants have been randomized to receive different doses of rezpegaldesleukin or a placebo. After this period, those patients demonstrating more than a 50% reduction in their Eczema Area and Severity Index (EASI) score have been re-randomized to receive ongoing treatment while continuing to assess their condition through to week 52.
Study Objectives
The primary objective of the Phase 2b study is to ascertain the mean improvement in EASI scores following the 16-week treatment. Secondary endpoints will be examined, such as the percentage of patients achieving a Validated Investigator Global Assessment (vIGA-AD) score of either 0 or 1, as well as those reaching EASI-75 and observing significant improvements in itch-related measures.
About Rezpegaldesleukin
Rezpegaldesleukin is poised as a first-in-class therapeutic option aimed at rectifying immune system imbalances in various autoimmune and inflammatory diseases. By targeting the interleukin-2 receptor complex, it encourages the proliferation of regulatory T cells, potentially steering the immune system towards a more balanced state.
Recently, the U.S. Food and Drug Administration (FDA) has designated rezpegaldesleukin with Fast Track status for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 and older, who have not found relief through topical treatments. Additionally, it has received similar status for severe alopecia areata in patients from 12 years onwards.
Market Presence and Future Applications
The ongoing development incorporates rezpegaldesleukin as a self-administered injection, broadening its potential application across multiple autoimmune and inflammatory conditions. It is entirely owned by Nektar Therapeutics, which also actively collaborates on various clinical trials involving several innovative therapeutic candidates.
The Impact of Atopic Dermatitis
Atopic dermatitis is recognized as the most prevalent form of eczema, influencing around 30 million individuals in the United States alone. This condition typically stems from an impaired skin barrier that allows allergens to penetrate, leading to inflammatory immune responses.
Nektar Therapeutics: Innovating Health Solutions
Nektar Therapeutics is dedicated to innovating therapies that address underlying immune dysfunctions associated with chronic inflammatory diseases. As a clinical-stage biotechnology company, it is exploring various pathways with rezpegaldesleukin, alongside other promising candidates in its expanding portfolio, such as NKTR-0165, NKTR-0166, and NKTR-422, aiming to foster advancements in treating these complex health challenges.
Frequently Asked Questions
What is Rezpegaldesleukin?
Rezpegaldesleukin is a potential first-in-class treatment targeting immune imbalances in autoimmune conditions by proliferating regulatory T cells.
What are the objectives of the REZOLVE-AD study?
The primary goal is to evaluate EASI score improvement, with additional focus on patient achievement of specific benchmarks related to eczema severity.
What is the significance of Fast Track designation by the FDA?
Fast Track designation expedites review and development for drugs that treat serious conditions and fulfill an unmet medical need, enhancing their availability to patients.
How many patients are involved in the trial?
The REZOLVE-AD Phase 2b study includes 393 participants with moderate-to-severe atopic dermatitis across various global sites.
What conditions are being targeted by Nektar Therapeutics?
Nektar is focused on treating autoimmune and inflammatory diseases, with ongoing research on various therapeutic candidates for multiple conditions.
